Pfizer COVID-19 vaccine 92% effective against Delta in teens

Credit: CC0 Public Domain

In a new study from the University of Arizona, researchers found for adolescents ages 12 to 17 years, the effectiveness of full vaccination with two doses of the Pfizer-BioNTech vaccine is 92% against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

In the study, the team tested 243 adolescents ages 12 to 17 years for SARS-CoV-2 each week, regardless of symptoms, and on the onset of COVID-19-like illness.

During the study, the B.1.617.2 (delta) variant was the predominant SARS-CoV-2 strain; 190, 30, and 66 adolescents contributed fully vaccinated person-time, partially vaccinated person-time, and unvaccinated person-time, respectively.

The researchers found that the estimated vaccine effectiveness of full Pfizer-BioNTech vaccination was 92% for preventing SARS-CoV-2 infection.

The team says the vaccine effectiveness estimates for the Pfizer-BioNTech vaccine during the period of delta variant predominance is very important.

The findings reinforce previous results that current vaccination efforts are resulting in substantial preventive benefits among adolescents aged 12 to 17 years.

If you care about COVID, please read studies about new way to prevent many COVID-19 variants, and COVID-19 vaccines need to be shored up with a plant-based diet.

For more information about the pandemic, please see recent studies about this new finding may help close door on COVID-19, and results showing green tea that could protect your body as a vaccine.

The study is published in Morbidity and Mortality Weekly Report. One author of the study is Karen Lutrick, Ph.D.

Copyright © 2021 Knowridge Science Report. All rights reserved.